Roseolovirus Vaccines

Creative Biolabs is a world leader in the field of viral vaccine development. With our extensive experience and advanced platform, we are therefore confident in offering the best vaccine development services for Roseoloviruses. We guarantee the finest results for our customers all over the world.

Roseoloviruses include Human Herpesvirus 6 (HHV-6) and Human Herpesvirus 7 (HHV-7). Fortunately, despite their widespread nature, these T lymphotropic and neurotropic viruses are generally regarded as benign infections, however, during some primary as well as secondary infections, reactivated infections in immunosuppressed patients could happen. This highlights the importance of their diagnosis and the role of better clinical care with available antiviral therapies, and the need for research or development of new vaccines targeting Roseolovirus.

Epidemiology for Roseoloviruses Infection

HHV-6 and HHV-7 are common paediatric infections. Maternal antibodies are present at birth, then decrease to 6 months of age, when the seropositive rate increases. With age, the serological titre appears to gradually decrease but persists, and the viruses establish lifelong infections characteristic like other herpesviruses. Up to 100% of adult populations are seropositive for these viruses. A similar pattern exists for HHV-7, although infection appears to occur later during infancy and early childhood, with seropositivity increasing to adulthood. Infection by HHV-6 or HHV-7 usually seems to give lifelong protective immunity. However, this may be largely dependent on the initial severity of the primary infection, route of infection and the nature of the specific response generated, as well as any later immune defects or modulation. Infection with HHV-6 does not appear to prevent subsequent infection with HHV-7, but it is possible, as it is with other related herpesviruses, that cross-reactive epitopes in some of the conserved proteins do generate cross protective responses that may reduce the severity of symptoms or lead to asymptomatic infection.

Fig.1 Roseoloviruses-host interactions.

Host Response to Roseoloviruses Infection

Aside from direct cellular lysis of permissive T lymphocytes, HHV-6 and HHV-7 can also have effects which perturb the function of immune cells. The killing of T lymphocytes can also be mediated by T cell apoptosis in a bystander effect induced by HHV-6- or HHV-7-infected cells. HHV-6 and HHV-7 can affect surface expression of CD3 and CD4 antigens, thus affecting immune activation and signal transduction. This immune escape mechanism can prevent detection of infected cells by cytotoxic T lymphocytes, thereby facilitating virus persistence. A number of cytokines are abnormally regulated in HHV-6 infected cells. These include downregulation of IL-2 synthesis, leading to suppression of cellular proliferation. HHV-6 can enhance NK cell activity through IL-15, where it also has upregulated CD4. HHV-6 virus infection can also upregulate TNF-kB receptors and chemokine receptors, EB1 or CCR7, which can further influence signalling in different cell types.

The Development of Roseoloviruses Vaccine

Primary infection with Roseoloviruses is nearly universal in early childhood. While the majority of infections are self-limited, the large number of infections coupled with the characteristic fever leads to significant healthcare utilization and possible antibiotic misuse. Because there's no vaccine to prevent Roseoloviruses. New methods for sensitive, specific and timely prevention of acute infection could potentially mitigate some of the healthcare expenditures and antimicrobial overuse. Additionally, research is most urgently needed to the development of Roseoloviruses Vaccine.

Creative Biolabs is pleased to share our cutting-edge technology and extensive expertise in the field of Roseoloviruses vaccine development and has focused on the viral vaccines for years. We can offer high-quality customized services by adjusting protocols to meet even the most specific requirements. If you are interested in our services, please contact us for more details.

Reference

1. Gompels U A. (2004). “Roseoloviruses: human herpesviruses 6 and 7”. Principles and Practice of Clinical Virology, Fifth Edition, 147-168.

All of our products can only be used for research purposes. These vaccine ingredients CANNOT be used directly on humans or animals.